Sight Sciences

SGHT on Nasdaq. Sight Sciences sells eye surgery and dry eye devices to eye doctors. Market value $491m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Not a fit for our list right now

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
-4.9%low

For every $100 of what the whole company costs, it produced $-4.95 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
-612.1%five-year median

Each dollar kept in the business earns -612 cents a year. Above 10 is good.

Quality score: 40 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$8.56 a share, 168% above its 1-year low

Over the past year the price has ranged from $3.19 to $9.71.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

-0.1
-0.1
-0.0
-0.0
-0.0
-0.0
2021202220232024202512 monthsto Jun '26
Revenue
$49m$71m$81m$80m$77m
Operating margin
-105.2%-117.7%-70.7%-63.3%-48.0%
Debt to equity
0.150.220.280.450.66
Shares outstanding
0.05bn0.05bn0.05bn0.05bn0.06bn

Health checks

  • Free cash flow positive0 of 5 years
  • Accounting checksSkipped: company is not yet profitable
  • Debt0.66× equity
  • Revenue growth, five yearsStrong, 12.1% a year
  • Buying back its own sharesNo, 14% more shares since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $23 million last quarter, up 20% on a year ago.
  • A loss of $4 million, compared with a loss of $12 million a year ago.
  • It loses 33 cents on each $1 of sales, compared with 64 cents a year earlier.
  • Over the past 12 months it spent $23 million more cash than it brought in, compared with $23 million a year earlier.
  • 5% more shares than a year ago. Each share owns a bit less of the company.
  • It has $29 million more cash than debt, down from $59 million a year ago.
  • Sales grew on a year ago in 3 of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$20m
December 2024$19m
March 2025$18m
June 2025$20m
September 2025$20m
December 2025$20m
March 2026$20m
June 2026$23m
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024-$11m
December 2024-$12m
March 2025-$14m
June 2025-$12m
September 2025-$8m
December 2025-$4m
March 2026-$13m
June 2026-$4m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
4 March 2026
Next quarterly (estimated, 10-Q)
4 November 2026

Who owns it

None of the long-term investors we follow own it. 112 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

5 investors own more than 5%.

  • Staffan Encrantz
    Passive investor
    at least 13.1%
    (filed with 2 related holders)
    Since 11 March 2025
    What they said

    The Fund acquired the Acquired Shares for investment purposes. One or more persons identified in Item 2 may buy or sell additional securities of the Issuer from time to time in open market or private transactions, depending on its evaluation of the Issuer's business, prospects…

    Read the filing
  • at least 6.0%+1.0 pts
    (filed with 1 related holder)
    Since 31 March 2025
  • BlackRock, Inc.
    Passive investor
    5.0%
    Since 31 December 2025
  • LONG FOCUS CAPITAL MASTER, LTD.
    Passive investor
    at least 3.7%
    (filed with 2 related holders)
    Since 16 January 2025
  • KCK LTD.
    Passive investor
    at least 2.7%−4.3 pts
    (filed with 1 related holder)
    Since 31 March 2026

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 1 insider bought $184,799 of shares on the open market. 6 sold $3m, $2m of it under preset trading plans.

  • Taylor Brenton
    EVP, Operations & R&D
    Sold
    under a preset trading plan
    Date
    2 October 2026
    Shares
    2,988
    Price
    $8.85
    Value
    $26,453
  • Bauerlein Alison
    Chief Operating Officer
    Sold
    under a preset trading plan
    Date
    2 October 2026
    Shares
    25,260
    Price
    $8.85
    Value
    $223,627
  • Rodberg James
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    2 October 2026
    Shares
    7,208
    Price
    $8.85
    Value
    $63,812
  • Badawi David
    Chief Technology Officer, Director
    Sold
    under a preset trading plan
    Date
    1 October 2026
    Shares
    7,797
    Price
    $9.05
    Value
    $70,555
  • Badawi Paul
    President and CEO, Director
    Sold
    under a preset trading plan
    Date
    1 October 2026
    Shares
    29,653
    Price
    $9.05
    Value
    $268,330
  • HAYDEN JEREMY B.
    Chief Legal Officer
    Sold
    under a preset trading plan
    Date
    6 July 2026
    Shares
    12,733
    Price
    $5.51
    Value
    $70,133
  • Badawi David
    Chief Technology Officer, Director
    Sold
    under a preset trading plan
    Date
    6 July 2026
    Shares
    7,418
    Price
    $5.51
    Value
    $40,858
  • Rodberg James
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    2 July 2026
    Shares
    6,902
    Price
    $5.36
    Value
    $36,995
  • Bauerlein Alison
    Chief Operating Officer
    Sold
    under a preset trading plan
    Date
    2 July 2026
    Shares
    24,184
    Price
    $5.36
    Value
    $129,626
  • Taylor Brenton
    EVP, Operations & R&D
    Sold
    under a preset trading plan
    Date
    1 July 2026
    Shares
    2,829
    Price
    $5.42
    Value
    $15,333

From Form 4 filings: insiders must report trades in their own company's shares within two days.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.